Please login to the form below

Not currently logged in
Email:
Password:

ataluren

This page shows the latest ataluren news and features for those working in and with pharma, biotech and healthcare.

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne

which markets Translarna (ataluren) in Europe.

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2014 Pharma deals during January 2014

    In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m. ... Ataluren was in clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics